Advertisement

Vaccines in the Immunocompromised Hosts

  • Paratosh Prasad
  • John Treanor
Chapter

Abstract

Vaccination remains the single most effective means available to prevent infectious diseases and mitigate their impact on the health of individuals. However, conditions that result in impairment of adaptive immunity both increase the risk and severity of these infections, as well as decreasing the efficacy of immunizations, posing unique challenges to medical care of these vulnerable patients. In addition, the complex relationships between the immunity of the subject and the mechanisms by which vaccines stimulate the immune system raise safety concerns as well, particularly related to the safety of live vaccines in this population, and the possibility that non-specific stimulation of the immune system could precipitate transplant rejection or increasing autoimmunity.

Keywords

Vaccines Efficacy Safety Immunocompromised HIV Solid organ transplant Hematologic transplant 

References

  1. 1.
    DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133(4):687–93.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Tasker SA, O’Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine. 1998;16:1039–42.PubMedCrossRefGoogle Scholar
  4. 4.
    Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011;52(1):128–37.PubMedCrossRefGoogle Scholar
  5. 5.
    de Lavallade H, Garland P, Sekine T, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Le Corre N, Thibault F, Pouteil Noble C, et al. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine. 2012;30(52):7522–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Karras NA, Weeres M, Sessions W, et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013;19(1):109–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96(6):896–904.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Siegrist CA, Ambrosioni J, Bel M, et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther. 2012;17(5):893–903.PubMedCrossRefGoogle Scholar
  10. 10.
    Salles MJ, Sens YA, Boas LS, Machado CM. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin Transpl. 2010;24(1):E17–23.CrossRefGoogle Scholar
  11. 11.
    Azevedo LS, Gerhard J, Miraglia JL, et al. Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors. Transpl Infect Dis. 2013;15(6):612–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29(9):1777–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52(2):248–56.PubMedCrossRefGoogle Scholar
  14. 14.
    GiaQuinta S, Michaels MG, McCullers JA, et al. Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2015;19(2):219–28.PubMedCrossRefGoogle Scholar
  15. 15.
    King JC, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000;181(2):725–8.PubMedCrossRefGoogle Scholar
  16. 16.
    King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001;20:1124–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25:590–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Talbot TR, Crocker DD, Peters J, et al. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Infect Control Hosp Epidemiol. 2005;26:494–500.PubMedCrossRefGoogle Scholar
  19. 19.
    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2016–17 influenza season. MMWR Recomm Rep. 2016;65(5):1–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A, et al. Response to vaccination against hepatitis B virus with a schedule of four 40-mug doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response. Transplant Proc. 2012;44(6):1499–501.PubMedCrossRefGoogle Scholar
  22. 22.
    Leung DH, Ton-That M, Economides JM, Healy CM. High prevalence of hepatitis B nonimmunity in vaccinated pediatric liver transplant recipients. Am J Transplant. 2015;15(2):535–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006;108(7):2470–5.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    O’Bryan TA, Rini EA, Okulicz J, et al. HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV Med. 2015;16(3):161–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Nevens F, Zuckerman JN, Burroughs AK, et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl. 2006;12(10):1489–95.PubMedCrossRefGoogle Scholar
  26. 26.
    Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008;8(2):235–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Di Paolo D, Lenci I, Cerocchi C, et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int. 2010;23(11):1105–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Ishigami M, Kamei H, Nakamura T, et al. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol. 2011;46(3):367–77.PubMedCrossRefGoogle Scholar
  29. 29.
    Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis. 2009;49(10):1550–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Wilck MB, Baden LR. Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Curr Opin Infect Dis. 2008;21(4):399–408.PubMedCrossRefGoogle Scholar
  31. 31.
    Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95(12):3683–6.PubMedGoogle Scholar
  32. 32.
    Torda A, Chong Q, Lee A, et al. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16(5):751–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Kondradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis. 1998;30(6):597–601.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodriguez-Barradas MC, Groover JE, Lacke CE, et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis. 1996;173(6):1347–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999;18(5–6):524–30.PubMedCrossRefGoogle Scholar
  36. 36.
    Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman J, Emmanuel PJ. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol. 2004;92:558–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Falcó V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine. 2006;24(14):2567–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Musher DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516–24.PubMedCrossRefGoogle Scholar
  39. 39.
    French N, Nakiyingi J, Carpenter LM, et al. 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106–11.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Teshale EH, Hanson D, Flannery B, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003. Vaccine. 2008;26(46):5830–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale R. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med. 1983;143(9):1735–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Avanzini MA, Carra AM, Maccario R, et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol. 1995;15(3):137–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Spoulou V, Victoratos P, Ioannidis JPA, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis. 2000;182(3):965–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Pao M, Papadopoulos EB, Chou J, et al. Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT).(Erratum appears in Biol Blood Marrow Transplant. 2008 Nov;14(11):1319). Biol Blood Marrow Transplant. 2008;14(9):1022–1030.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2007;109(6):2322–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Lujan M, Burgos J, Gallego M, et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis. 2013;57(12):1722–30.PubMedCrossRefGoogle Scholar
  47. 47.
    Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48(10):1392–401.PubMedCrossRefGoogle Scholar
  48. 48.
    Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28(15):2730–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Gattringer R, Winkler H, Roedler S, Jaksch P, Herkner H, Burgmann H. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants. Transpl Infect Dis. 2011;13(5):540–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J. 2009;28(8):688–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis. 2008;47(7):885–92.PubMedCrossRefGoogle Scholar
  52. 52.
    French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362(9):812–22.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31:3594–602.PubMedCrossRefGoogle Scholar
  54. 54.
    Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84(2):657–63.PubMedGoogle Scholar
  55. 55.
    Machado CM, Gonçalves FB, Pannuti CS, Dulley FL, de Souza VAUF. Measles in bone marrow transplant recipients during an outbreak in São Paulo Brazil. Blood. 2002;99(1):83–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Ljungman P, Aschan J, Barkholt L, et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant. 2004;34(7):589–93.PubMedCrossRefGoogle Scholar
  57. 57.
    Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 1989;261(17):2512–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Fowlkes A, Witte D, Beeler J, et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. J Infect Dis. 2011;204(Suppl 1):S149–57.PubMedCrossRefGoogle Scholar
  59. 59.
    Helfand RF, Witte D, Fowlkes A, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis. 2008;198(10):1457–65.PubMedCrossRefGoogle Scholar
  60. 60.
    Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci. 2009;106(19):7939–44.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis. 2001;32(7):1090–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with aids. Ann Intern Med. 1998;129(2):104–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Goon P, Cohen B, Jin L, Watkins R, Tudor-Williams G. MMR vaccine in HIV-infected children—potential hazards? Vaccine. 2001;19(28–29):3816–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Mori K, Kawamura K, Honda M, Sasaki N. Responses in children to measles vaccination associated with perirenal transplantation. Pediatr Int. 2009;51(5):617–20.PubMedCrossRefGoogle Scholar
  65. 65.
    Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer. 2004;101(3):635–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Cheng FWT, Leung TF, Chan PKS, et al. Recovery of humoral and cellular immunities to vaccine-preventable infectious diseases in pediatric oncology patients. Pediatr Hematol Oncol. 2010;27(3):195–204.PubMedCrossRefGoogle Scholar
  67. 67.
    Kawamura K, Yamazaki R, Akahoshi Y, et al. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients. Hematology. 2015;20(2):77–82.PubMedCrossRefGoogle Scholar
  68. 68.
    Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35(8):787–91.PubMedCrossRefGoogle Scholar
  69. 69.
    Shinjoh M, Hoshino K, Takahashi T, Nakayama T. Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2015;33(5):701–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Kumar D. Immunizations following solid-organ transplantation. Curr Opin Infect Dis. 2014;27(4):329–35.PubMedCrossRefGoogle Scholar
  71. 71.
    Control CD. General recommendations on immunization. Morbid Mortal Wkly Rep – Rep Recomm. 2011;60:RR2:1–61.Google Scholar
  72. 72.
    Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–81.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Myers MG. Viremia caused by varicella-zoster virus: association with malignant progressive varicella. J Infect Dis. 1979;140(2):229–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Hamborsky J, Kroger A, Wolfe S. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington, DC: Public Health Foundation; 2015.Google Scholar
  75. 75.
    Takahashi M. Current status and prospects of live varicella vaccine. Vaccine. 1992;10(14):1007–14.PubMedCrossRefGoogle Scholar
  76. 76.
    Merck. VARIVAX prescriber information. 2013. Accessed 1/6/2017.Google Scholar
  77. 77.
    Merck. ProQuad prescriber information. 2016. Accessed 1/6/17.Google Scholar
  78. 78.
    Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics. 1986;78(4 Pt 2):757–62.PubMedGoogle Scholar
  79. 79.
    Takahashi M. Clinical overview of varicella vaccine: development and early studies. Pediatrics. 1986;78(4 Pt 2):736–41.PubMedGoogle Scholar
  80. 80.
    Gershon AA, Steinberg SP, Gelb L, et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA. 1984;252(3):355–62.PubMedCrossRefGoogle Scholar
  81. 81.
    Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989;320(14):892–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991;325(22):1545–50.PubMedCrossRefGoogle Scholar
  83. 83.
    Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20(5):381–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17(11):1708–13.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45(11):1602–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Naidus E, Damon L, Schwartz BS, Breed C, Liu C. Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87(1):123–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood. 1986;67(3):582–7.PubMedGoogle Scholar
  88. 88.
    Lum LG, Seigneuret MC, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol. 1986;6(5):389–96.PubMedCrossRefGoogle Scholar
  89. 89.
    Johnston BL, Conly JM. Immunization for bone marrow transplant recipients. Can J Infect Dis. 2002;13(6):353–7.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Tseng HF, Luo Y, Shi J, et al. Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis. 2016;62(4):462–7.PubMedGoogle Scholar
  91. 91.
    Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.PubMedCrossRefGoogle Scholar
  92. 92.
    Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32.PubMedCrossRefGoogle Scholar
  93. 93.
    Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–9.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Diaz PS, Au D, Smith S, Amylon M, Link M, Arvin AM. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics. 1991;87(2):166–70.PubMedGoogle Scholar
  95. 95.
    Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19(7–8):916–23.PubMedCrossRefGoogle Scholar
  96. 96.
    Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992;90(2 Pt 1):216–20.PubMedGoogle Scholar
  97. 97.
    Agger PE. Summary basis for regulatory action. 2011. Accessed 1/8/17.Google Scholar
  98. 98.
    Visser LG. The immunosuppressed traveler. Infect Dis Clin N Am. 2012;26(3):609–24.CrossRefGoogle Scholar
  99. 99.
    Rosen J. Travel medicine and the solid-organ transplant recipient. Infect Dis Clin N Am. 2013;27(2):429–57.CrossRefGoogle Scholar
  100. 100.
    Aung AK, Trubiano JA, Spelman DW. Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ transplant and haematopoeitic stem cell transplant recipients): a review. Travel Med Infect Dis. 2015;13(1):31–47.PubMedCrossRefGoogle Scholar
  101. 101.
    Staples JE, Monath TP, Gershman MD, Barrett ADT. Yellow fever vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. Philadelphia: Elsevier; 2017.Google Scholar
  102. 102.
    Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798–805.PubMedCrossRefGoogle Scholar
  103. 103.
    Kengsakul K, Sathirapongsasuti K, PUnyagupta S. Fatal myeloencephalitis following yellow fever vacation in a case with HIV infection. J Med Assoc Thail. 2002;85:131–4.Google Scholar
  104. 104.
    Azevedo LS, Lasmar EP, Contieri FL, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14(3):237–41.PubMedCrossRefGoogle Scholar
  105. 105.
    Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol. 2004;72(4):299–301.PubMedCrossRefGoogle Scholar
  106. 106.
    Yax JA, Farnon EC, Cary Engleberg N. Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow fever vaccine. J Travel Med. 2009;16(5):365–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Wyplosz B, Burdet C, Francois H, et al. Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation. Am J Transplant. 2013;13(9):2458–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Infectious DiseasesUniversity of Rochester Medical CenterRochesterUSA

Personalised recommendations